Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.64 |
| ▸ | F13A1 | P00488 | 8/20 | 0.64 |
| ▸ | TGM1 | P22735 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25085726 | 0.86 | TGM2 (0.64) | TGM2F13A1TGM1STSGPR119 | |
| SCHEMBL30049771 | 0.84 | NAMPT (0.55) | TGM2F13A1TGM1POLBGPR119 | |
| SCHEMBL18701970 | 0.84 | ALDH1A1 (0.61) | TGM2F13A1TGM1ALDH1A1CYP2D6 | |
| SCHEMBL5253160 | 0.84 | POLB (0.70) | TGM2F13A1TGM1POLBSTS | |
| SCHEMBL16899 | 0.83 | ALDH1A1 (0.49) | TGM2F13A1TGM1ALDH1A1CYP2D6 | |
| SCHEMBL18711635 | 0.82 | ALDH1A1 (0.65) | ALDH1A1CYP2D6POLBCHRM1 | |
| SCHEMBL3210642 | 0.81 | TGM2 (0.59) | TGM2F13A1TGM1POLBSTS | |
| SCHEMBL1979361 | 0.81 | POLB (0.67) | ALDH1A1CYP2D6POLBCHRM1 | |
| SCHEMBL29361285 | 0.80 | MAPT (0.57) | ALDH1A1POLBGPR119 | |
| SCHEMBL1115181 | 0.80 | MAPT (0.57) | ALDH1A1POLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-7683067-B2 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | ASTRAZENECA AB (SE) | 2010-03-23 | — | — | US | disclosed |
| WO-2009085185-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | CDK4, CDKL4, CDK2 | TGM2 2760/4885F13A1 4240/4885TGM1 2278/4885 |
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | GSK3B, GSK3A, GSKIP | TGM2 2415/4885F13A1 3442/4885TGM1 1081/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | TGM2 2760/4885F13A1 4240/4885TGM1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.